| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | MK-2206 | GDSC1000 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |